奥沙利铂联合替吉奥治疗晚期胃癌的效果

EFFICACY OF COMBINED OXALIPLATIN AND TEGAFUR GIMERACIL OTERACIL POTASSIUM IN THE TREATMENT OF ADVANCED GASTRIC CANCER

目的探讨奥沙利铂联合替吉奥治疗晚期胃癌的效果。方法 2011年3月-2013年1月,我院收治的晚期胃癌病人56例,随机分为实验组和对照组,每组28例。实验组采用奥沙利铂联合替吉奥治疗,而对照组采用FOLFOX4方案治疗。结果两组疗效比较差异无显著性(P>0.05),而两组的肿瘤控制率比较差异有显著性(χ2=2.13,P<0.05);两组不良反应主要为恶心呕吐、腹泻、末梢神经炎、血小板减少、血红蛋白减少、白细胞减少;实验组FACT-G评分提高率及降低率明显高于对照组(χ2=6.23、5.72,P<0.05)。结论奥沙利铂联合替吉奥治疗晚期胃癌具有协同作用,其疗效满意,可以明显提高肿瘤控制率并减少药物毒性。

Objective To assess the effect of combined Oxaliplatin with Tegafur Gimeracil Oteracil Potassium （TGOP） for advanced gastric cancer （AGC）. Methods From Mar. 2011 to Jan. 2013, 56 AGC patients treated in our hospital were divi ded into experimental group and control group in random. The patients in the experimental group were treated with Oxaliplatin plus TGOP, and those in the control group treated with OI.FOX4 protocol. Results A comparison between the two groups showed no significant difference with regard to the therapeutic result （P〉0.05）, and the difference was significant between the two groups in terms of the tumor control rate （X2 =2.13,P〈0.05）. The untoward reactions of both groups were nausea and vomitting, diar- rhoea, peripheral neuritis, thrombocytopenia, decreased hemoglobin and aleucocytosis. The increase and decrease rate of FACT-G of the experiment group was higher than the control group （X2 =6.23,5.72;P〈0.05）. Conclusion Oxaliplatin plus TGOP show joint action in treating late gastric cancer with satisfied therapeutic effect, obviously increase tumor control rate and reduce drug toxicity.